Program in Chemical Sciences, Chulabhorn Graduate Institute, Chulabhorn Royal Academy, Bangkok 10210, Thailand.
Program in Applied Biological Sciences, Chulabhorn Graduate Institute, Chulabhorn Royal Academy, Bangkok 10210, Thailand; National Omics Center, National Science and Technology Development Agency, Pathum Thani 12120, Thailand.
Bioorg Chem. 2021 May;110:104795. doi: 10.1016/j.bioorg.2021.104795. Epub 2021 Mar 4.
Virtual screening of commercially available molecular entities by using CDRUG, structure-based virtual screening, and similarity identified eight new derivatives of 3-phenyl-1H-indole-2-carbohydrazide with anti-proliferative activities. The molecules were tested experimentally for inhibition of tubulin polymerisation, which revealed furan-3-ylmethylene-3-phenyl-1H-indole-2-carbohydrazide (27a) as the most potent candidate. Molecule 27a was able to induce G2/M phase arrest in A549 cell line, similar to other tubulin inhibitors. Synthetic modifications of 27a were focussed on small substitutions on the furan ring, halogenation at R position and alteration of furyl connectivity. Derivatives 27b, 27d and 27i exhibited the strongest tubulin inhibition activities and were comparable to 27a. Bromine substitution at R position showed most prominent anticancer activities; derivatives 27b-27d displayed the strongest activities against HuCCA-1 cell line and were more potent than doxorubicin and the parent molecule 27a with IC values <0.5 μM. Notably, 27b with a 5-methoxy substitution on furan displayed the strongest activity against HepG2 cell line (IC = 0.34 µM), while 27d displayed stronger activity against A549 cell line (IC = 0.43 µM) compared to doxorubicin and 27a. Fluorine substitutions at the R position tended to show more modest anti-tubulin and anticancer activities, and change of 2-furyl to 3-furyl was tolerable. The new derivatives, thiophenyl 26, displayed the strongest activity against A549 cell line (IC = 0.19 µM), while 1-phenylethylidene 21b and 21c exhibited more modest anticancer activities with unclear mechanisms of action; 26 and 21c demonstrated G2/M phase arrest, but showed weak tubulin inhibitory properties. Molecular docking suggests the series inhibit tubulin at the colchicine site, in agreement with the experimental findings. The calculated molecular descriptors indicated that the molecules obey Lipinski's rule which suggests the molecules are drug-like structures.
通过使用 CDRUG、基于结构的虚拟筛选和相似性,对商业可得的分子实体进行虚拟筛选,鉴定出具有抗增殖活性的 3-苯基-1H-吲哚-2-甲酰肼的 8 种新衍生物。这些分子被实验测试了抑制微管蛋白聚合的活性,结果表明呋喃-3-亚甲基-3-苯基-1H-吲哚-2-甲酰肼(27a)是最有效的候选物。分子 27a 能够诱导 A549 细胞系中的 G2/M 期阻滞,与其他微管蛋白抑制剂类似。27a 的合成修饰集中在呋喃环上的小取代、R 位的卤化和呋喃连接的改变上。衍生物 27b、27d 和 27i 表现出最强的微管蛋白抑制活性,与 27a 相当。R 位的溴取代显示出最显著的抗癌活性;衍生物 27b-27d 对 HuCCA-1 细胞系表现出最强的活性,并且比多柔比星和母体分子 27a 更有效,IC 值<0.5μM。值得注意的是,在呋喃上具有 5-甲氧基取代的 27b 对 HepG2 细胞系显示出最强的活性(IC=0.34µM),而 27d 对 A549 细胞系的活性(IC=0.43µM)强于多柔比星和 27a。R 位的氟取代往往显示出更温和的抗微管蛋白和抗癌活性,并且 2-呋喃基变为 3-呋喃基是可以容忍的。新衍生物噻吩 26 对 A549 细胞系显示出最强的活性(IC=0.19µM),而 1-苯乙基亚甲基 21b 和 21c 表现出更温和的抗癌活性,作用机制尚不清楚;26 和 21c 显示出 G2/M 期阻滞,但表现出较弱的微管蛋白抑制特性。分子对接表明该系列化合物在秋水仙碱位点抑制微管蛋白,与实验结果一致。计算得到的分子描述符表明这些分子符合 Lipinski 规则,表明这些分子是类药性结构。